The impact of COVID-19 on patients with neuromyelitis optica spectrum disorder; a pilot study.
Identifieur interne : 000203 ( Main/Exploration ); précédent : 000202; suivant : 000204The impact of COVID-19 on patients with neuromyelitis optica spectrum disorder; a pilot study.
Auteurs : Anna Tomczak [États-Unis] ; May H. Han [États-Unis]Source :
- Multiple sclerosis and related disorders [ 2211-0356 ] ; 2020.
Descripteurs français
- KwdFr :
- Adulte (MeSH), Aggravation transitoire des symptômes (MeSH), Betacoronavirus (MeSH), Enquêtes et questionnaires (MeSH), Femelle (MeSH), Humains (MeSH), Infections à coronavirus (psychologie), Infections à coronavirus (épidémiologie), Mâle (MeSH), Neuromyélite optique (complications), Pandémies (MeSH), Pneumopathie virale (psychologie), Pneumopathie virale (épidémiologie), Projets pilotes (MeSH).
- MESH :
- psychologie : Infections à coronavirus, Pneumopathie virale.
- épidémiologie : Infections à coronavirus, Pneumopathie virale.
- complications : Adulte, Aggravation transitoire des symptômes, Betacoronavirus, Enquêtes et questionnaires, Femelle, Humains, Mâle, Neuromyélite optique, Pandémies, Projets pilotes.
English descriptors
- KwdEn :
- Adult (MeSH), Betacoronavirus (MeSH), COVID-19 (MeSH), Coronavirus Infections (epidemiology), Coronavirus Infections (psychology), Female (MeSH), Humans (MeSH), Male (MeSH), Neuromyelitis Optica (complications), Pandemics (MeSH), Pilot Projects (MeSH), Pneumonia, Viral (epidemiology), Pneumonia, Viral (psychology), Psychological Distress (MeSH), SARS-CoV-2 (MeSH), Surveys and Questionnaires (MeSH), Symptom Flare Up (MeSH).
- MESH :
- complications : Neuromyelitis Optica.
- epidemiology : Coronavirus Infections, Pneumonia, Viral.
- psychology : Coronavirus Infections, Pneumonia, Viral.
- Adult, Betacoronavirus, COVID-19, Female, Humans, Male, Pandemics, Pilot Projects, Psychological Distress, SARS-CoV-2, Surveys and Questionnaires, Symptom Flare Up.
Abstract
Neuromyelitis optica spectrum disorder (NMOSD) is a CNS neuroinflammatory disorder, mediated by the pathogenic autoantibody aquaporin-4 (AQP4-IgG). Current treatment includes long-term use of immunomodulatory therapies, leading to increased rates of infections among this population. It is of interest therefore, to study how the COVID-19 pandemic affects NMOSD patients in terms of their disease activity. A 15-point questionnaire was administered to 33 participants living in Northern California with NMOSD, MS and other related disorders. Although none of the participants were diagnosed with COVID-19, our results show that 2 participants with NMOSD experienced new onset of neurological symptoms and 2 experienced worsening of previous neurological symptoms - suggesting a possible effect of pandemic-related stress on this CNS autoimmune disorder.
DOI: 10.1016/j.msard.2020.102347
PubMed: 32645636
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">The impact of COVID-19 on patients with neuromyelitis optica spectrum disorder; a pilot study.</title><author><name sortKey="Tomczak, Anna" sort="Tomczak, Anna" uniqKey="Tomczak A" first="Anna" last="Tomczak">Anna Tomczak</name><affiliation wicri:level="4"><nlm:affiliation>Department of Neurology and Neurological Sciences, Stanford University, Stanford, CA, United States.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology and Neurological Sciences, Stanford University, Stanford, CA</wicri:regionArea><placeName><region type="state">Californie</region><settlement type="city">Stanford (Californie)</settlement></placeName><orgName type="university">Université Stanford</orgName></affiliation></author><author><name sortKey="Han, May H" sort="Han, May H" uniqKey="Han M" first="May H" last="Han">May H. Han</name><affiliation wicri:level="4"><nlm:affiliation>Department of Neurology and Neurological Sciences, Stanford University, Stanford, CA, United States; Neuroimunology Division, Multiple Sclerosis Center, Stanford University, Stanford, CA, United States. Electronic address: mayhan@stanford.edu.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology and Neurological Sciences, Stanford University, Stanford, CA, United States; Neuroimunology Division, Multiple Sclerosis Center, Stanford University, Stanford, CA</wicri:regionArea><placeName><region type="state">Californie</region><settlement type="city">Stanford (Californie)</settlement></placeName><orgName type="university">Université Stanford</orgName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32645636</idno><idno type="pmid">32645636</idno><idno type="doi">10.1016/j.msard.2020.102347</idno><idno type="wicri:Area/Main/Corpus">000525</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000525</idno><idno type="wicri:Area/Main/Curation">000525</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000525</idno><idno type="wicri:Area/Main/Exploration">000525</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">The impact of COVID-19 on patients with neuromyelitis optica spectrum disorder; a pilot study.</title><author><name sortKey="Tomczak, Anna" sort="Tomczak, Anna" uniqKey="Tomczak A" first="Anna" last="Tomczak">Anna Tomczak</name><affiliation wicri:level="4"><nlm:affiliation>Department of Neurology and Neurological Sciences, Stanford University, Stanford, CA, United States.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology and Neurological Sciences, Stanford University, Stanford, CA</wicri:regionArea><placeName><region type="state">Californie</region><settlement type="city">Stanford (Californie)</settlement></placeName><orgName type="university">Université Stanford</orgName></affiliation></author><author><name sortKey="Han, May H" sort="Han, May H" uniqKey="Han M" first="May H" last="Han">May H. Han</name><affiliation wicri:level="4"><nlm:affiliation>Department of Neurology and Neurological Sciences, Stanford University, Stanford, CA, United States; Neuroimunology Division, Multiple Sclerosis Center, Stanford University, Stanford, CA, United States. Electronic address: mayhan@stanford.edu.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology and Neurological Sciences, Stanford University, Stanford, CA, United States; Neuroimunology Division, Multiple Sclerosis Center, Stanford University, Stanford, CA</wicri:regionArea><placeName><region type="state">Californie</region><settlement type="city">Stanford (Californie)</settlement></placeName><orgName type="university">Université Stanford</orgName></affiliation></author></analytic><series><title level="j">Multiple sclerosis and related disorders</title><idno type="eISSN">2211-0356</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult (MeSH)</term><term>Betacoronavirus (MeSH)</term><term>COVID-19 (MeSH)</term><term>Coronavirus Infections (epidemiology)</term><term>Coronavirus Infections (psychology)</term><term>Female (MeSH)</term><term>Humans (MeSH)</term><term>Male (MeSH)</term><term>Neuromyelitis Optica (complications)</term><term>Pandemics (MeSH)</term><term>Pilot Projects (MeSH)</term><term>Pneumonia, Viral (epidemiology)</term><term>Pneumonia, Viral (psychology)</term><term>Psychological Distress (MeSH)</term><term>SARS-CoV-2 (MeSH)</term><term>Surveys and Questionnaires (MeSH)</term><term>Symptom Flare Up (MeSH)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte (MeSH)</term><term>Aggravation transitoire des symptômes (MeSH)</term><term>Betacoronavirus (MeSH)</term><term>Enquêtes et questionnaires (MeSH)</term><term>Femelle (MeSH)</term><term>Humains (MeSH)</term><term>Infections à coronavirus (psychologie)</term><term>Infections à coronavirus (épidémiologie)</term><term>Mâle (MeSH)</term><term>Neuromyélite optique (complications)</term><term>Pandémies (MeSH)</term><term>Pneumopathie virale (psychologie)</term><term>Pneumopathie virale (épidémiologie)</term><term>Projets pilotes (MeSH)</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Neuromyelitis Optica</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="psychologie" xml:lang="fr"><term>Infections à coronavirus</term><term>Pneumopathie virale</term></keywords><keywords scheme="MESH" qualifier="psychology" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Infections à coronavirus</term><term>Pneumopathie virale</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Betacoronavirus</term><term>COVID-19</term><term>Female</term><term>Humans</term><term>Male</term><term>Pandemics</term><term>Pilot Projects</term><term>Psychological Distress</term><term>SARS-CoV-2</term><term>Surveys and Questionnaires</term><term>Symptom Flare Up</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="fr"><term>Adulte</term><term>Aggravation transitoire des symptômes</term><term>Betacoronavirus</term><term>Enquêtes et questionnaires</term><term>Femelle</term><term>Humains</term><term>Mâle</term><term>Neuromyélite optique</term><term>Pandémies</term><term>Projets pilotes</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Neuromyelitis optica spectrum disorder (NMOSD) is a CNS neuroinflammatory disorder, mediated by the pathogenic autoantibody aquaporin-4 (AQP4-IgG). Current treatment includes long-term use of immunomodulatory therapies, leading to increased rates of infections among this population. It is of interest therefore, to study how the COVID-19 pandemic affects NMOSD patients in terms of their disease activity. A 15-point questionnaire was administered to 33 participants living in Northern California with NMOSD, MS and other related disorders. Although none of the participants were diagnosed with COVID-19, our results show that 2 participants with NMOSD experienced new onset of neurological symptoms and 2 experienced worsening of previous neurological symptoms - suggesting a possible effect of pandemic-related stress on this CNS autoimmune disorder.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32645636</PMID><DateCompleted><Year>2020</Year><Month>10</Month><Day>29</Day></DateCompleted><DateRevised><Year>2020</Year><Month>12</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2211-0356</ISSN><JournalIssue CitedMedium="Internet"><Volume>45</Volume><PubDate><Year>2020</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Multiple sclerosis and related disorders</Title><ISOAbbreviation>Mult Scler Relat Disord</ISOAbbreviation></Journal><ArticleTitle>The impact of COVID-19 on patients with neuromyelitis optica spectrum disorder; a pilot study.</ArticleTitle><Pagination><MedlinePgn>102347</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S2211-0348(20)30422-3</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.msard.2020.102347</ELocationID><Abstract><AbstractText>Neuromyelitis optica spectrum disorder (NMOSD) is a CNS neuroinflammatory disorder, mediated by the pathogenic autoantibody aquaporin-4 (AQP4-IgG). Current treatment includes long-term use of immunomodulatory therapies, leading to increased rates of infections among this population. It is of interest therefore, to study how the COVID-19 pandemic affects NMOSD patients in terms of their disease activity. A 15-point questionnaire was administered to 33 participants living in Northern California with NMOSD, MS and other related disorders. Although none of the participants were diagnosed with COVID-19, our results show that 2 participants with NMOSD experienced new onset of neurological symptoms and 2 experienced worsening of previous neurological symptoms - suggesting a possible effect of pandemic-related stress on this CNS autoimmune disorder.</AbstractText><CopyrightInformation>Published by Elsevier B.V.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tomczak</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University, Stanford, CA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Han</LastName><ForeName>May H</ForeName><Initials>MH</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University, Stanford, CA, United States; Neuroimunology Division, Multiple Sclerosis Center, Stanford University, Stanford, CA, United States. Electronic address: mayhan@stanford.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>06</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Mult Scler Relat Disord</MedlineTA><NlmUniqueID>101580247</NlmUniqueID><ISSNLinking>2211-0348</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="N">Betacoronavirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009471" MajorTopicYN="N">Neuromyelitis Optica</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010865" MajorTopicYN="N">Pilot Projects</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000079225" MajorTopicYN="Y">Psychological Distress</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000067251" MajorTopicYN="Y">Symptom Flare Up</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Infection</Keyword><Keyword MajorTopicYN="N">Neuromyelitis optica spectrum disorder</Keyword><Keyword MajorTopicYN="N">Pandemic</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>05</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>06</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>06</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>7</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>10</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>7</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32645636</ArticleId><ArticleId IdType="pii">S2211-0348(20)30422-3</ArticleId><ArticleId IdType="doi">10.1016/j.msard.2020.102347</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>États-Unis</li></country><region><li>Californie</li></region><settlement><li>Stanford (Californie)</li></settlement><orgName><li>Université Stanford</li></orgName></list><tree><country name="États-Unis"><region name="Californie"><name sortKey="Tomczak, Anna" sort="Tomczak, Anna" uniqKey="Tomczak A" first="Anna" last="Tomczak">Anna Tomczak</name></region><name sortKey="Han, May H" sort="Han, May H" uniqKey="Han M" first="May H" last="Han">May H. Han</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidStanfordV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000203 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000203 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidStanfordV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:32645636
|texte= The impact of COVID-19 on patients with neuromyelitis optica spectrum disorder; a pilot study.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:32645636" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a CovidStanfordV1
| This area was generated with Dilib version V0.6.38. |  |